Form 4: Stoke Therapeutics Director Sells Shares Under 10b5-1 Plan

Stoke Therapeutics Director Adrian R. Krainer sold 40,472 shares of common stock for approximately $1.09 million under a pre-arranged 10b5-1 trading plan.

Summary

• Adrian R. Krainer, a Director of Stoke Therapeutics, Inc. (STOK), reported transactions involving the company's common stock.
• On November 14, 2025, Krainer disposed of a total of 40,472 shares of common stock.
• The first transaction involved the sale of 19,790 shares at a weighted average price of $26.6141 per share, totaling approximately $526,791.
• The price for the first sale ranged from $25.975 to $26.97 per share.
• The second transaction involved the sale of 20,682 shares at a weighted average price of $27.3361 per share, totaling approximately $565,310.
• The price for the second sale ranged from $26.98 to $27.88 per share.
• The total value of shares sold across both transactions is approximately $1,092,101.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Krainer on August 15, 2025.
• Following these reported transactions, Krainer beneficially owns 364,246 shares of Stoke Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is generally considered neutral news. It does not indicate any specific positive or negative developments for the company.

Future Outlook

This Form 4 filing reports historical insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual director's planned stock sale within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale by a director could be perceived as a minor signal, but given it's a 10b5-1 plan, it's typically not seen as a reflection of management's immediate outlook on the company's prospects. The total shares sold represent a small fraction of the company's outstanding shares.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Sale, 10b5-1 Plan, Director Transaction, Equity Sale